Advanced Malignancies
Conditions
Brief summary
The purpose of this study is to evaluate safety, tolerability and efficacy of IBI323(anti-LAG-3/PD-L1) or in combination with chemotherapy in participants with advanced malignancies. Another purpose is to determine the pharmacokinetics,pharmacodynamics and immunogenicity of IBI323
Interventions
DRUGIBI323
In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Phase Ia Patients with locally advanced, recurrent or metastatic solid tumors who have failed standard treatment Phase Ib cohort A Patients with IO-refractory advanced NSCLC cohort B Patients with IO-naive advanced NSCLC who have failed standard treatment cohort C Patients with advanced NSCLC who have no prior treatment and PD-L1 TPS≥1% cohort D Patients with ES-SCLC or G3 neuroendocrine tumors who have failed standard treatment cohort E Patients with advanced MPM who have failed standard treatment cohort F Patients with advanced UC who have failed standard treatment cohort G Patients with advanced nccRCC who have failed standard treatment cohort H Patients with advanced HCC who have failed standard treatment cohort I Patients with advanced NPC who have failed standard treatment cohort J Patients with advanced CC or HNSCC who have failed standard treatment cohort K Patients with advanced GC or GEJC with HER2 negative who have no prior treatment cohort L Patients with advanced TNBC who have failed standard treatment 2. Able to understand and willing to sign the ICF. 3. 18 to 75 years old. 4. Life expectancy at least 12 weeks. 5. At least 1 measurable lesion per RECIST v1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Adequate organ and bone marrow functionAdequate organ and bone marrow function.
Exclusion criteria
1. Prior treatment with any anti- LAG-3 antibody. 2. Prior immunotherapy treatment for Stage Ia extension cohort ( immunotherapy untreated) and Stage Ib cohort B-L 3. Any investigational drugs received within 4 weeks prior to the first study treatment. 4. Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of study therapy. 5. Symptomatic CNS metastasis. 6. History of autoimmune disease , present active autoimmune disease or inflammatory diseases 7. Pregnant or nursing females.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) | 24 months | To evaluate the safety and tolerability of IBI323 \[Adverse events (AEs), treatment-related AE (TRAE), immune-related AEs (irAE), serious adverse event (SAE), dose-limiting toxicity (DLT) assessed by CTCAE v5.0\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigator Assessments of Overall Response Rate(ORR) | 24 months | RECIST v1.1 will be used to determine ORR by investigator |
| Disease Control Rate(DCR) | 24 months | RECIST v1.1 will be used to determine DCR by investigator |
| PFS (progression-free survival) | 24 months | RECIST v1.1 will be used to determine PFS by investigator |
| Anti-drug antibody (ADA) | 24 months | — |
Countries
China
Contacts
Primary Contactyu Wang
Outcome results
None listed